+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pompe Disease Market - Global Forecast 2026-2032- Product Image
Pompe Disease Market - Global Forecast 2026-2032- Product Image
Sale

Pompe Disease Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968988
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pompe Disease Market is projected to reach USD 3.70 Billion in 2026. It is expected to continue growing at a CAGR of 5.43%, reaching USD 5.09 Billion by 2032.

Pompe disease is a rare, inherited lysosomal storage disorder caused by pathogenic variants in the GAA gene, leading to deficient acid alpha-glucosidase activity and glycogen accumulation in skeletal, cardiac, and respiratory muscle. Published epidemiology commonly cites an overall frequency near 1 in 40,000 births, with meaningful variation by ethnicity, founder effects, and newborn screening methodology.

The Pompe disease landscape is shaped by three clinical realities: infantile-onset Pompe disease can progress rapidly and is often fatal without timely therapy, late-onset Pompe disease is frequently underdiagnosed because symptoms overlap with neuromuscular and respiratory disorders, and lifelong treatment requires coordinated specialty care. Enzyme replacement therapy, newborn screening, genetic testing, respiratory monitoring, immunogenicity management, and multidisciplinary disease care remain central to patient outcomes and strategic planning.

Transformative Shifts in the Pompe Disease Landscape

The Pompe disease landscape is undergoing a measurable transition from symptom-led diagnosis to earlier identification through newborn screening, enzymatic testing, dried blood spot assays, and confirmatory molecular diagnostics. The addition of Pompe disease to the U.S. Recommended Uniform Screening Panel in 2015 accelerated state-level newborn screening adoption and strengthened the evidence base for early treatment, especially in infantile-onset disease.

Treatment competition is also evolving. Long-established alglucosidase alfa therapy created the foundation for disease-modifying care, while newer options such as avalglucosidase alfa and cipaglucosidase alfa plus miglustat have increased attention on improved glycogen clearance, durability, infusion burden, immunogenicity management, and patient-centered outcomes. These shifts are moving stakeholders toward value-based differentiation rather than simple treatment availability.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the Pompe disease ecosystem by improving how rare disease signals are detected across electronic health records, laboratory data, claims histories, and imaging workflows. AI-enabled pattern recognition can help flag patients with unexplained hyperCKemia, limb-girdle weakness, hypertrophic cardiomyopathy, respiratory insufficiency, sleep-disordered breathing, or repeated specialist visits, supporting earlier referral for GAA enzyme testing and genetic confirmation.

In drug development and real-world evidence, AI can accelerate patient stratification, natural history modeling, biomarker discovery, and trial feasibility assessment. Its impact remains cumulative rather than instantaneous because Pompe disease datasets are small, privacy-sensitive, and heterogeneous; therefore, the greatest near-term value will come from validated clinical decision support, federated data models, and transparent algorithms aligned with regulatory and ethical expectations.

Key Regional Insights for Pompe Disease

North America remains a leading region for Pompe disease diagnosis and treatment adoption due to broad specialty-center access, payer coverage for approved enzyme replacement therapies, patient advocacy infrastructure, and newborn screening momentum across the United States. Canada benefits from universal health systems, clinical genetics capacity, and rare disease frameworks, although access and reimbursement timing can differ by province.

Europe demonstrates strong clinical infrastructure through neuromuscular centers, cross-border research networks, national rare disease plans, and European Medicines Agency oversight. The European Union supports coordinated rare disease policy and European Reference Networks, while the United Kingdom, Germany, France, Italy, and Spain contribute significant clinical expertise in diagnosis, respiratory care, and long-term follow-up. Asia-Pacific is expanding as Japan, South Korea, Australia, China, and India improve genetic testing capacity, reimbursement pathways, newborn screening pilots, and rare disease policy recognition. Latin America shows growing demand led by Brazil and Mexico, but uneven specialist access, fragmented reimbursement, and delayed diagnosis remain barriers. The Middle East, particularly Gulf countries, is increasing rare disease investment through genomics programs and tertiary hospitals, while Africa continues to face diagnostic capacity constraints, limited therapy access, lower awareness of late-onset Pompe disease, and underdeveloped referral networks.

Key Group Insights Across Global Health Alliances

Within ASEAN, rising investment in newborn screening, genomic medicine, and tertiary neuromuscular centers is improving Pompe disease identification, although access remains uneven between metropolitan and rural populations and across public and private health systems. GCC countries are prioritizing rare disease programs through national genomics initiatives, specialized hospitals, and public reimbursement models, which is relevant because consanguinity can increase the visibility of autosomal recessive disorders, including lysosomal storage diseases.

The European Union provides one of the most coordinated policy environments for Pompe disease through orphan drug regulation, health technology assessment, cross-border care mechanisms, and European Reference Networks. BRICS markets represent both opportunity and complexity: China, India, and Brazil offer large undiagnosed patient populations and expanding diagnostics, while reimbursement, clinical referral pathways, and regional access vary widely; Russia and South Africa add further diversity in public-sector capacity and rare disease prioritization. G7 countries generally lead in approved therapy availability, evidence generation, newborn screening infrastructure, and specialist multidisciplinary care. NATO membership does not directly define healthcare access, but many NATO countries overlap with advanced European and North American rare disease systems, supporting stronger clinical research collaboration, emergency preparedness, and biologics supply-chain resilience.

Key Country Insights in Pompe Disease

The United States leads in newborn screening scale, FDA-approved therapy access, patient advocacy, clinical trial participation, and real-world evidence generation. Canada has strong specialty care, public health systems, and clinical genetics networks, but province-specific reimbursement dynamics can influence treatment timing. Mexico and Brazil are important Latin American settings where public-sector access, reference-center capacity, diagnostic delays, and judicialization in Brazil influence treatment pathways and continuity of care.

In Europe, the United Kingdom, Germany, France, Italy, and Spain have established neuromuscular expertise, reimbursement systems, respiratory care pathways, and rare disease networks, while Russia’s access environment is more variable across regions. China is expanding rare disease policy, genetic testing, newborn screening research, and domestic clinical studies; India has a large potential undiagnosed population but faces affordability, awareness, and access challenges. Japan and South Korea are advanced Asia-Pacific settings with strong regulatory systems, specialist centers, and newborn screening experience, and Australia benefits from organized rare disease care, public reimbursement mechanisms, clinical genetics infrastructure, and national attention to genomic medicine.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize earlier diagnosis by partnering with newborn screening programs, neuromuscular clinics, pulmonologists, cardiologists, metabolic specialists, and genetic testing providers. Commercial and medical strategies should support clear diagnostic algorithms, dried blood spot testing, reflex genetic confirmation, family cascade testing, and education on late-onset Pompe disease to reduce multi-year diagnostic delays.

Therapy differentiation should be anchored in outcomes that matter to patients, clinicians, and payers, including ventilator-free survival in infantile-onset disease, motor function, respiratory function, fatigue, mobility, infusion burden, safety, immunogenicity, and quality of life. Organizations should invest in real-world evidence registries, equitable access programs, decentralized monitoring, home-infusion readiness where clinically appropriate, and compliant AI tools that improve case finding without compromising privacy or clinical accountability.

Research Methodology

This executive summary is developed through secondary research and expert synthesis of verified public sources, including regulatory agency materials from the FDA and EMA, newborn screening guidance, peer-reviewed Pompe disease literature, orphan disease registries, clinical guideline publications, and health technology assessment references. Insights are triangulated across epidemiology, approved therapies, diagnostic standards, reimbursement dynamics, newborn screening implementation, and regional healthcare infrastructure.

The methodology emphasizes data integrity over speculative claims. Findings are interpreted using rare disease analysis, clinical pathway mapping, policy review, and comparative regional assessment. Where quantitative estimates vary, the summary uses conservative, widely cited ranges and highlights geographic variability rather than presenting unsupported projections.

Conclusion

The Pompe disease landscape is moving toward earlier detection, more differentiated treatment, and evidence-driven access. Newborn screening, molecular diagnostics, enzyme replacement innovation, respiratory monitoring, and multidisciplinary care are redefining outcomes for both infantile-onset and late-onset Pompe disease.

For stakeholders, the strongest opportunities lie in reducing diagnostic delay, proving real-world value, expanding equitable access, and integrating responsible AI into rare disease workflows. Organizations that align clinical evidence, patient experience, and payer expectations will be best positioned in the evolving Pompe disease landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Pompe Disease Market, by Product
7.1. Introduction
7.2. Enzyme Replacement Therapy
7.2.1. Alglucosidase Alfa
7.2.2. Avalglucosidase Alfa
7.2.3. Cipaglucosidase Alfa
7.3. Gene Therapy
7.3.1. In Vivo Gene Transfer
7.3.2. Ex Vivo Gene-Modified Cell Therapy
7.4. Next-Generation Enzyme Therapies
7.5. Pharmacological Chaperones
7.6. Substrate Reduction Therapy
7.7. mRNA/Protein Expression Therapies
7.8. Supportive/Adjunctive Care
8. Pompe Disease Market, by Patient Type
8.1. Introduction
8.2. Infantile Onset
8.3. Late Onset
9. Pompe Disease Market, by Treatment Regimen
9.1. Introduction
9.2. Biweekly Infusion
9.3. Monthly Infusion
10. Pompe Disease Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Intramuscular
10.5. Subcutaneous
10.6. Inhaled
11. Pompe Disease Market, by Diagnostic Pathway
11.1. Introduction
11.2. Newborn Screening
11.2.1. Dried Blood Spot Enzyme Assay
11.2.2. Reflex Genetic Testing
11.3. Diagnostic Testing & Symptom Onset
11.3.1. Enzyme Activity Assay
11.3.2. Genetic Testing
11.3.3. Biomarker Testing
11.3.4. Imaging & Functional Testing
11.3.5. Tissue Biopsy
11.4. Treatment Monitoring
12. Pompe Disease Market, by Site of Care
12.1. Introduction
12.2. Hospital Inpatient
12.3. Standalone Infusion Center
12.4. Home Infusion
12.5. Specialty Clinic (Metabolic/Neuromuscular)
13. Pompe Disease Market, by Region
13.1. Asia-Pacific
13.2. Europe
13.3. North America
13.4. Latin America
13.5. Africa
13.6. Middle East
14. Pompe Disease Market, by Group
14.1. NATO
14.2. G7
14.3. European Union
14.4. BRICS
14.5. ASEAN
14.6. GCC
15. Pompe Disease Market, by Country
15.1. United States
15.2. China
15.3. Germany
15.4. Japan
15.5. India
15.6. United Kingdom
15.7. France
15.8. Canada
15.9. Italy
15.10. Australia
15.11. South Korea
15.12. Brazil
15.13. Mexico
15.14. Russia
15.15. Spain
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Sanofi SA
17.2. BioMarin Pharmaceutical Inc.
17.3. Revvity, Inc.
17.4. Maze Therapeutics, Inc.
17.5. Laboratory Corporation of America Holdings
17.6. Baebies, Inc.
17.7. GENETHON
17.8. Aro Biotherapeutics
17.9. Astellas Pharma Inc.
17.10. Bayer AG
17.11. Bio-Rad Laboratories, Inc.
17.12. Bio-Techne Corporation
17.13. Catalent, Inc.
17.14. Charles River Laboratories International, Inc.
17.15. Denali Therapeutics Inc.
17.16. Eurofins Scientific SE
17.17. Illumina, Inc.
17.18. LaCAR MDx Technologies S.A.
17.19. Novartis AG
17.20. QIAGEN N.V.
17.21. Quest Diagnostics Incorporated
17.22. Shionogi & Co., Ltd.
17.23. Siemens Healthineers AG
17.24. Thermo Fisher Scientific Inc.
17.25. Valerion Therapeutics, LLC
17.26. WuXi AppTec
List of Figures
FIGURE 1. GLOBAL POMPE DISEASE MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL POMPE DISEASE MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL POMPE DISEASE MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL POMPE DISEASE MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL POMPE DISEASE MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
FIGURE 7. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2032 (%)
FIGURE 11. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2025 VS 2032 (%)
FIGURE 15. GLOBAL POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2025 VS 2032 (%)
FIGURE 17. GLOBAL POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL POMPE DISEASE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL POMPE DISEASE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL POMPE DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL ENZYME REPLACEMENT THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL ALGLUCOSIDASE ALFA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL ALGLUCOSIDASE ALFA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL ALGLUCOSIDASE ALFA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL AVALGLUCOSIDASE ALFA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL AVALGLUCOSIDASE ALFA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL AVALGLUCOSIDASE ALFA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CIPAGLUCOSIDASE ALFA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL CIPAGLUCOSIDASE ALFA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL CIPAGLUCOSIDASE ALFA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL GENE THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL GENE THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL GENE THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL IN VIVO GENE TRANSFER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL IN VIVO GENE TRANSFER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL IN VIVO GENE TRANSFER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL EX VIVO GENE-MODIFIED CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL EX VIVO GENE-MODIFIED CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL EX VIVO GENE-MODIFIED CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL NEXT-GENERATION ENZYME THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL NEXT-GENERATION ENZYME THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL NEXT-GENERATION ENZYME THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PHARMACOLOGICAL CHAPERONES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PHARMACOLOGICAL CHAPERONES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PHARMACOLOGICAL CHAPERONES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL SUBSTRATE REDUCTION THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL MRNA/PROTEIN EXPRESSION THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL MRNA/PROTEIN EXPRESSION THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL MRNA/PROTEIN EXPRESSION THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL SUPPORTIVE/ADJUNCTIVE CARE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SUPPORTIVE/ADJUNCTIVE CARE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SUPPORTIVE/ADJUNCTIVE CARE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INFANTILE ONSET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INFANTILE ONSET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INFANTILE ONSET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL LATE ONSET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL LATE ONSET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL LATE ONSET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL BIWEEKLY INFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL BIWEEKLY INFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL BIWEEKLY INFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL MONTHLY INFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL MONTHLY INFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL MONTHLY INFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL INHALED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL INHALED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL INHALED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL NEWBORN SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL NEWBORN SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL NEWBORN SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL DRIED BLOOD SPOT ENZYME ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL DRIED BLOOD SPOT ENZYME ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL DRIED BLOOD SPOT ENZYME ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL REFLEX GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL REFLEX GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL REFLEX GENETIC TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL DIAGNOSTIC TESTING & SYMPTOM ONSET MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL DIAGNOSTIC TESTING & SYMPTOM ONSET MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL DIAGNOSTIC TESTING & SYMPTOM ONSET MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL ENZYME ACTIVITY ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ENZYME ACTIVITY ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ENZYME ACTIVITY ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL GENETIC TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL GENETIC TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL GENETIC TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL BIOMARKER TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL BIOMARKER TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL BIOMARKER TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL IMAGING & FUNCTIONAL TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL IMAGING & FUNCTIONAL TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL IMAGING & FUNCTIONAL TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL TISSUE BIOPSY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL TISSUE BIOPSY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL TISSUE BIOPSY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL TREATMENT MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL TREATMENT MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL TREATMENT MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL HOSPITAL INPATIENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL HOSPITAL INPATIENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL HOSPITAL INPATIENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL STANDALONE INFUSION CENTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL STANDALONE INFUSION CENTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL STANDALONE INFUSION CENTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL HOME INFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL HOME INFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL HOME INFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL SPECIALTY CLINIC (METABOLIC/NEUROMUSCULAR) MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL SPECIALTY CLINIC (METABOLIC/NEUROMUSCULAR) MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL SPECIALTY CLINIC (METABOLIC/NEUROMUSCULAR) MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL POMPE DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 115. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 117. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 126. EUROPE POMPE DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 127. EUROPE POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 128. EUROPE POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 129. EUROPE POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 130. EUROPE POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 131. EUROPE POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 132. EUROPE POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 133. EUROPE POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 134. EUROPE POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 135. EUROPE POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 136. EUROPE POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 144. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 145. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 146. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 147. NORTH AMERICA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 156. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 157. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 158. LATIN AMERICA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 159. AFRICA POMPE DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 160. AFRICA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 161. AFRICA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 162. AFRICA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 163. AFRICA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 164. AFRICA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 165. AFRICA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 166. AFRICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 167. AFRICA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 168. AFRICA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 169. AFRICA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 180. MIDDLE EAST POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 181. GLOBAL POMPE DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. NATO POMPE DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 183. NATO POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 184. NATO POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 185. NATO POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 186. NATO POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 187. NATO POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 188. NATO POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 189. NATO POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 190. NATO POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 191. NATO POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 192. NATO POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 193. G7 POMPE DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. G7 POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 195. G7 POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 196. G7 POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 197. G7 POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 198. G7 POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 199. G7 POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 200. G7 POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 201. G7 POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 202. G7 POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 203. G7 POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 215. BRICS POMPE DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 216. BRICS POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 217. BRICS POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 218. BRICS POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 219. BRICS POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 220. BRICS POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 221. BRICS POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 222. BRICS POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 223. BRICS POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 224. BRICS POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 225. BRICS POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 226. ASEAN POMPE DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 227. ASEAN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 228. ASEAN POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 229. ASEAN POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 230. ASEAN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 231. ASEAN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 232. ASEAN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 233. ASEAN POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 234. ASEAN POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 235. ASEAN POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 236. ASEAN POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 237. GCC POMPE DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 238. GCC POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 239. GCC POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 240. GCC POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 241. GCC POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 242. GCC POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 243. GCC POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 244. GCC POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 245. GCC POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 246. GCC POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 247. GCC POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 248. GLOBAL POMPE DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 249. UNITED STATES POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. UNITED STATES POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 251. UNITED STATES POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 252. UNITED STATES POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 253. UNITED STATES POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 254. UNITED STATES POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 255. UNITED STATES POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 256. UNITED STATES POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 257. UNITED STATES POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 258. UNITED STATES POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 259. UNITED STATES POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 260. CHINA POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 261. CHINA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 262. CHINA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 263. CHINA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 264. CHINA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 265. CHINA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 266. CHINA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 267. CHINA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 268. CHINA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 269. CHINA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 270. CHINA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 271. GERMANY POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 272. GERMANY POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 273. GERMANY POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 274. GERMANY POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 275. GERMANY POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 276. GERMANY POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 277. GERMANY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 278. GERMANY POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 279. GERMANY POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 280. GERMANY POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 281. GERMANY POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 282. JAPAN POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 283. JAPAN POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 284. JAPAN POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 285. JAPAN POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 286. JAPAN POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 287. JAPAN POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 288. JAPAN POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 289. JAPAN POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 290. JAPAN POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 291. JAPAN POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 292. JAPAN POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 293. INDIA POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 294. INDIA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 295. INDIA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 296. INDIA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 297. INDIA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 298. INDIA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 299. INDIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 300. INDIA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 301. INDIA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 302. INDIA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 303. INDIA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 304. UNITED KINGDOM POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 305. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 306. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 307. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 308. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 309. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 310. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 311. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 312. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 313. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 314. UNITED KINGDOM POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 315. FRANCE POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 316. FRANCE POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 317. FRANCE POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 318. FRANCE POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 319. FRANCE POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 320. FRANCE POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 321. FRANCE POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 322. FRANCE POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 323. FRANCE POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 324. FRANCE POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 325. FRANCE POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 326. CANADA POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 327. CANADA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 328. CANADA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 329. CANADA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 330. CANADA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 331. CANADA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 332. CANADA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 333. CANADA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 334. CANADA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 335. CANADA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 336. CANADA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 337. ITALY POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 338. ITALY POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 339. ITALY POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 340. ITALY POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 341. ITALY POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 342. ITALY POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 343. ITALY POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 344. ITALY POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 345. ITALY POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 346. ITALY POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 347. ITALY POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 348. AUSTRALIA POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 349. AUSTRALIA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 350. AUSTRALIA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 351. AUSTRALIA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 352. AUSTRALIA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 353. AUSTRALIA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION)
TABLE 354. AUSTRALIA POMPE DISEASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 355. AUSTRALIA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC PATHWAY, 2017-2032 (USD MILLION)
TABLE 356. AUSTRALIA POMPE DISEASE MARKET SIZE, BY NEWBORN SCREENING, 2017-2032 (USD MILLION)
TABLE 357. AUSTRALIA POMPE DISEASE MARKET SIZE, BY DIAGNOSTIC TESTING & SYMPTOM ONSET, 2017-2032 (USD MILLION)
TABLE 358. AUSTRALIA POMPE DISEASE MARKET SIZE, BY SITE OF CARE, 2017-2032 (USD MILLION)
TABLE 359. SOUTH KOREA POMPE DISEASE MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 360. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY PRODUCT, 2017-2032 (USD MILLION)
TABLE 361. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, 2017-2032 (USD MILLION)
TABLE 362. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY GENE THERAPY, 2017-2032 (USD MILLION)
TABLE 363. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY PATIENT TYPE, 2017-2032 (USD MILLION)
TABLE 364. SOUTH KOREA POMPE DISEASE MARKET SIZE, BY TREATMENT REGIMEN, 2017-2032 (USD MILLION

Companies Mentioned

  • Sanofi SA
  • BioMarin Pharmaceutical Inc.
  • Revvity, Inc.
  • Maze Therapeutics, Inc.
  • Laboratory Corporation of America Holdings
  • Baebies, Inc.
  • GENETHON
  • Aro Biotherapeutics
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Catalent, Inc.
  • Charles River Laboratories International, Inc.
  • Denali Therapeutics Inc.
  • Eurofins Scientific SE
  • Illumina, Inc.
  • LaCAR MDx Technologies S.A.
  • Novartis AG
  • QIAGEN N.V.
  • Quest Diagnostics Incorporated
  • Shionogi & Co., Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Valerion Therapeutics, LLC
  • WuXi AppTec

Table Information

Report AttributeDetails
No. of Pages190
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 3.7 Billion
Forecasted Market Value ( USD ) by 2032 $ 5.09 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Pompe Disease - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Pompe Disease - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 115 Pages
  • Global
From
Pompe Disease Market Outlook 2026-2034: Market Share, and Growth Analysis by Route of Administration (Oral, Parenteral), Therapy Type, Disease Onset Type, Distribution Channel - Product Image

Pompe Disease Market Outlook 2026-2034: Market Share, and Growth Analysis by Route of Administration (Oral, Parenteral), Therapy Type, Disease Onset Type, Distribution Channel

  • Report
  • 160 Pages
  • Global
From
Pompe Disease Market Report 2026 - Product Image

Pompe Disease Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Pompe Disease Treatment Market Size by Treatment, Route of Administration, Distribution Channel, Indication Type, and Region 2026-2034 - Product Image

Pompe Disease Treatment Market Size by Treatment, Route of Administration, Distribution Channel, Indication Type, and Region 2026-2034

  • Report
  • 142 Pages
  • Global
From
Pompe Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F - Product Image

Pompe Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

  • Report
  • 182 Pages
  • Global
From

About the Pompe Disease Drug Market

Pompe Disease is a rare, inherited disorder caused by a deficiency of the enzyme alpha-glucosidase. This deficiency leads to the accumulation of glycogen in the lysosomes of cells, resulting in progressive muscle weakness and respiratory failure. Endocrine and Metabolic Disorders Drugs are used to treat Pompe Disease. These drugs are designed to replace the missing enzyme, allowing the body to break down the accumulated glycogen and restore normal muscle function. The Pompe Disease Drug market is a rapidly growing segment of the Endocrine and Metabolic Disorders Drugs market. The increasing prevalence of Pompe Disease and the availability of effective treatments have driven the growth of this market. Companies in this market are focused on developing treatments that are safe and effective, as well as improving existing treatments. Some companies in the Pompe Disease Drug market include Sanofi, Pfizer, Amicus Therapeutics, and Ultragenyx Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.